Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial

INTRODUCTION: Over the last two decades, there has been no novel acute treatment for migraine to address the large unmet medical need in Chinese patients. Lasmiditan, a novel selective serotonin 1F receptor agonist (ditan), is anticipated to bring clinical benefit in Chinese patients with migraine....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tingmin, He, Li, Yang, Xiaosu, Zhou, Jiying, Luo, Guogang, Wang, Hebo, Zhao, Hongru, Hu, Quan, Ji, Fei, Yu, Shengyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338201/
https://www.ncbi.nlm.nih.gov/pubmed/35713760
http://dx.doi.org/10.1007/s40120-022-00369-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338201/
https://www.ncbi.nlm.nih.gov/pubmed/35713760
http://dx.doi.org/10.1007/s40120-022-00369-1

Ejemplares similares